S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients (2015/1/14)|
|Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments (2015/2/26)|
|Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy (2015/1/12)|
|Sarepta Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors (2015/1/7)|
|Sarepta Therapeutics to Present Company Overview at the 2015 33rd Annual J.P. Morgan Healthcare Conference (2015/1/5)|
|Sarepta Therapeutics to Present Company Overview at Upcoming Conferences (2015/2/4)|
|Sarepta Therapeutics to Present Company Overview at Upcoming Conferences (2015/2/24)|
|Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update on February 26, 2015 (2015/2/19)|
|SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 (2015/1/2)|
|INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP (2014/12/8)|
Click above to view more mutual fund data and stats for srpt - Sarepta Therapeutics Inc.